Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

上海谊众(688091.SH):冻干粉针剂(抗肿瘤药)通过药品生产质量管理规范符合性检查
Shanghai Yizhong (688091.SH): freeze-dried powder injection (antineoplastic drugs) passes the compliance test of drug production quality control standards.

智通財經 ·  {{timeTz}}

智通财经APP讯,上海谊众(688091.SH)发布公告,公司于11月19日正式获得《上海市药品监督管理局药品生产现场检查结果告知书》:公司已通过上海市药品监督管理局于2021年4月26日—30日对公司上海市奉贤区仁齐路79号:冻干粉针剂(抗肿瘤药)开展的药品生产质量管理规范符合性检查,检查结果符合《药品生产质量管理规范》要求。

Zhitong Finance and Economics APP, Shanghai Yizhong (688091.SH) issued an announcement, the company officially obtained the "notice of Drug production site Inspection results of Shanghai Drug Administration" on November 19: the company has carried out compliance inspection of drug production quality management standards carried out by Shanghai Drug Administration on April 26-30, 2021, No. 79 Renqi Road, Fengxian District, Shanghai: freeze-dried powder injection (antineoplastic drugs). The inspection results meet the requirements of "Drug production quality Management Standard".

公司核心产品“注射用紫杉醇聚合物胶束”已于11月22日完成首张处方,正式开展销售工作。

The company's core product, "Paclitaxel Polymer Micelle for injection", completed its first prescription on November 22 and officially launched the sales work.

This page is machine-translated. Moomoo tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.